

**EFFECTS OF ENVIRONMENTAL TEMPERATURE ON
PHARMACOKINETICS OF, AND CLINICAL RESPONSE TO
XYLAZINE IN GOATS.**

A Thesis

submitted to the Faculty of Veterinary Science,

University of Pretoria, Onderstepoort,

in partial fulfilment of the requirements for the degree of

Doctor of Philosophy.

by

Eddy Geoffrey Mosoti Mogo

B.V.M., University of Nairobi, 1986

M.Sc., (Clinical Studies), University of Nairobi, 1990.

May, 1999



DECLARATION

I, **Eddy Geoffrey Mosoti Mogo**, do hereby declare that this thesis which I submit to the University of Pretoria, for the degree of Ph.D has not been submitted either in part or as a whole by me for a degree to any other university and my promoters: Prof. A. Guthrie - Equine Research Centre, Prof. G. F. Stegmann - Department of Surgery, and Prof. G. Swan - Department of Pharmacology and Toxicology, bear testimony to that.

Signed.....*Eddy G Mogo*..... Date.....*26.05.99*.....



Dedicated to my wife Judith Waithera, son Eric and daughter Alainer.

Thank you for understanding and bearing with my long periods of absence.

ACKNOWLEDGEMENTS

First, I would like to thank the Kenya Government and the I.D.A/I.B.R.D of the World Bank for their financial support to enable me to undertake these studies. I would also like to thank the University of Pretoria's Faculty of Veterinary Science for accepting me to undertake these studies in their institution.

I offer my sincere gratitude to my supervisors, Prof. G.F. Stegmann - Department of Surgery, Prof. A. Guthrie - Equine Research Centre, and Prof. G. Swan - Department of Pharmacology and Toxicology for their time, support and guidance. You were always there for me and thank you.

Many thanks also go to Bayer - Animal Health Division, South Africa, for their financial and material support, Dr J. Louw and the support staff of the Onderstepoort Veterinary Academic Research Unit, Prof. S.S. van den Berg and staff of the Department of Surgery, Jane Nurton and staff of the Equine Research Centre, Mr Phillip Minnaar and staff of the Department of Pharmacology and Toxicology and the many people who directly or indirectly contributed to the successful completion of this project. To you all, I shall always be most grateful.

TABLE OF CONTENTS

DECLARATION.....	ii
DEDICATION.....	iii
ACKNOWLEDGEMENTS.....	iv
TABLE OF CONTENTS.....	v
LIST OF FIGURES.....	xiv
LIST OF TABLES.....	xvi
ABSTRACT.....	xvii
CHAPTER ONE: GENERAL INTRODUCTION.....	1
CHAPTER TWO: LITERATURE REVIEW.....	8
2.1 INTRODUCTION.....	8
2.1.1 STRESS.....	8
2.1.2 PHYSIOLOGY OF TEMPERATURE REGULATION.....	10
2.1.3 HOMEOTHERMY.....	11
2.1.4 THERMAL BALANCE.....	11
2.1.5 TEMPERATURE RECEPTORS.....	12
2.1.6 HEAT BALANCE DURING ANAESTHESIA.....	12
2.1.7 TEMPERATURE MONITORING.....	16
2.1.8 TEMPERATURE MONITORING SITES.....	16

2.1.9 THERMOMETERS.....	17
2.2 XYLAZINE HYDROCHLORIDE.....	17
2.2.1 CLASSIFICATION.....	18
2.2.2 PHARMACOLOGIC PROPERTIES.....	18
2.2.3 ABSORPTION.....	19
2.2.4 METABOLISM AND ELIMINATION.....	19
2.2.5 PHARMACOKINETICS.....	20
2.2.6 DETERMINATION OF XYLAZINE HYDROCHLORIDE IN BIOLOGICAL MATERIALS.....	21
2.3 BEHAVIOURAL AND CLINICAL EFFECTS OF XYLAZINE IN ANIMALS.....	23
2.3.1 INTRODUCTION.....	23
2.3.2 SEDATION.....	24
2.3.3 SALIVATION.....	27
2.3.4 ANALGESIA.....	28
2.3.5 URINATION.....	30
2.4 EFFECTS OF XYLAZINE ON HAEMATOLOGY AND CARDIOPULMONARY FUNCTION.....	30
2.5 EFFECTS OF XYLAZINE ON ARTERIAL BLOOD GAS TENSIONS AND ACID-BASE BALANCE.....	36
2.6 EFFECTS OF XYLAZINE ON PLASMA GLUCOSE	

AND INSULIN.....	40
2.7 XYLAZINE HYDROCHLORIDE AND BODY TEMPERATURE.....	43
CHAPTER THREE: CLINICAL,CARDIOPULMONARY AND HAEMOCYTOLOGIC EFFECTS OF XYLAZINE HYROCHLORIDE IN GOATS UNDER DIFFERENT ENVIRONMENTAL TEMPERATURE AND HUMIDITY CONDITIONS.....	49
3.1 INTRODUCTION.....	49
3.2 MATERIALS AND METHODS.....	51
3.2.1 EXPERIMENTAL ANIMALS.....	52
3.2.2 SURGICAL RELOCATION OF THE CAROTID ARTERIES.....	53
3.2.3 EXPERIMENTAL PROCEDURE.....	54
3.2.3.1 EXPERIMENTAL DESIGN.....	54
3.2.3.2 TREATMENT PHASES.....	54
3.2.4 STATISTICAL ANALYSIS.....	57
3.3 RESULTS.....	58
3.3.1 CLINICAL AND BEHAVIOURAL EFFECTS.....	58
3.3.2 CARDIOPULMONARY AND HAEMOCYTOLOGICAL EFFECTS.....	61

3.4	DISCUSSION.....	73
3.4.1	CLINICAL AND BEHAVIOURAL EFFECTS.....	73
3.4.1.1	SEDATION.....	73
3.4.1.2	SALIVATION.....	75
3.4.1.3	ANALGESIA.....	76
3.4.1.4	URINATION.....	78
3.4.2	CARDIOPULMONARY AND HAEMOCYTOLOGICAL EFFECTS.....	80

CHAPTER FOUR: EFFECTS OF XYLAZINE HYDROCHLORIDE
ON ACID-BASE BALANCE AND ARTERIAL BLOOD GAS
TENSIONS IN GOATS UNDER DIFFERENT ENVIRONMENTAL
TEMPERATURE AND HUMIDITY CONDITIONS.....

		87
4.1	INTRODUCTION.....	87
4.2	MATERIALS AND METHODS.....	88
4.2.1	ANIMALS.....	88
4.2.2	SURGICAL RELOCATION OF THE CAROTID ARTERIES....	89
4.2.3	EXPERIMENTAL PROCEDURE.....	89
4.2.3.1	EXPERIMENTAL DESIGN.....	89
4.2.3.2	TREATMENTS PHASES	89

4.2.4	STATISTICAL ANALYSIS.....	92
4.3	RESULTS.....	93
4.3.1	CLINICAL AND BAHAVIOURAL EFFECTS.....	93
4.3.2	ARTERIAL BLOOD GAS TENSIONS AND ACID-BASE BALANCE.....	93
4.4	DISCUSSION.....	98
4.4.1	ARTERIAL GAS TENSIONS AND ACID-BASE BALANCE.....	98

CHAPTER FIVE: THE HYPERGLYCAEMIC AND

HYPOINSULINAEMIC EFFECTS OF XYLAZINE

HYDROCHLORIDE IN GOATS UNDER DIFFERENT

ENVIRONMENTAL TEMPERATURE AND HUMIDITY

	CONDITIONS.....	103
5.1	INTRODUCTION.....	103
5.2	MATERIALS AND METHODS.....	103
5.2.1	ANIMALS.....	103
5.2.2	EXPERIMENTAL PROCEDURE.....	105
5.2.2.1	EXPERIMENTAL DESIGN.....	105
5.2.2.2	TREATMENTS PHASES.....	106
5.2.2.3	RADIOIMMUNOASSAY PROCEDURE FOR	

THE DETERMINATION OF PLASMA	
INSULIN CONCENTRATION.....	
	108
5.2.3	STATISTICAL ANALYSIS..... 109
5.3	RESULTS..... 110
5.3.1	CLINICAL AND BEHAVIOURAL EFFECTS..... 110
5.3.2	EFFECTS OF XYLAZINE ON PLASMA GLUCOSE
	AND INSULIN..... 110
5.4	DISCUSSION..... 116
CHAPTER SIX: THE EFFECT OF DIFFERENT AMBIENT	
TEMPERATURE AND HUMIDITY	
CONDITIONS ON THERMAL RESPONSES TO	
XYLAZINE IN GOATS..... 121	
6.1	INTRODUCTION..... 121
6.2	MATERIALS AND METHODS..... 122
6.2.1	ANIMALS..... 122
6.2.2	EXPERIMENTAL PROCEDURE..... 123
6.2.2.1	EXPERIMENTAL DESIGN..... 123
6.2.2.2	TREATMENTS PHASES..... 124
6.2.3	STATISTICAL ANALYSIS..... 126
6.3	RESULTS..... 127

6.3.1	CLINICAL AND BEHAVIOURAL EFFECTS.....	127
6.3.2	EFFECTS OF XYLAZINE ON BODY TEMPERATURE.....	127
6.4	DISCUSSION.....	133

CHAPTER SEVEN: THE EFFECTS OF AMBIENT TEMPERATURE

	AND HUMIDITY ON THE PHARMACOKINETICS OF XYLAZINE IN GOATS.....	139
7.1	INTRODUCTION.....	139
7.2	MATERIALS AND METHODS.....	141
7.2.1	ANIMALS.....	141
7.2.2	EXPERIMENTAL DESIGN.....	142
7.2.3	TREATMENT PHASES.....	142
7.2.4	MEASUREMENT OF XYLAZINE CONTENT IN PLASMA...144	
7.2.4.1	INTRODUCTION.....	144
7.2.4.2	REAGENTS.....	145
7.2.4.3	INSTRUMENTATION.....	146
7.2.4.4	HPLC CONDITIONS.....	147
7.2.4.5	STOCK SOLUTIONS, SECONDARY XYLAZINE SOLUTIONS AND REFERENCE SAMPLES.....	147
7.2.4.6	EXTRACTION PROCEDURE AND EFFICIENCY.....	148
7.2.4.7	CALIBRATION PROCEDURE.....	150

7.2.4.8	LIMIT OF DETECTION AND LINEARITY.....	151
7.2.4.9	ACCURACY, PRECISION AND REPRODUCIBILITY.....	151
7.2.4.10	<i>IN VITRO</i> QUALITY CONTROL SAMPLES.....	152
7.2.5	PHARMACOKINETIC ANALYSIS.....	152
7.2.6	STATISTICAL ANALYSES.....	154
7.3	RESULTS.....	155
7.3.1	HPLC VALIDATION RESULTS.....	155
7.3.1.1	CHARACTERISTICS OF CALIBRATION CURVES AND LINEARITY.....	155
7.3.1.2	SPECIFICITY AND SENSITIVITY.....	155
7.3.1.3	ACCURACY AND PRECISION.....	156
7.3.1.4	REPEATABILITY.....	159
7.3.1.5	EXTRACTION EFFICIENCY.....	159
7.3.2	INTRAVASCULAR DISPOSITION OF XYLAZINE.....	160
7.4	DISCUSSION.....	165
7.4.1	HPLC ANALYTICAL METHOD.....	165
7.4.2	PHARMACOKINETIC RESULTS.....	168
CHAPTER EIGHT:	GENERAL CONCLUSIONS.....	173



ANNEXURE..... 177

REFERENCES..... 180

LIST OF FIGURES

3.1	Temporal changes in mean and standard error of mean of heart rate of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	63
3.2	Temporal changes in mean and standard error of mean arterial blood pressure of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	64
3.3	Temporal changes in mean and standard error of mean of systolic blood pressure of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	65
3.4	Temporal changes in mean and standard error of mean of diastolic blood pressure of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	66
3.5	Temporal changes in mean and standard error of mean of respiratory rate of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	67
5.1	Temporal changes in mean and standard error of mean of plasma glucose concentration of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	112

5.2	Temporal changes in mean and standard error of mean of plasma insulin concentration of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	114
6.1	Temporal changes in mean and standard error of mean of oesophageal temperature of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	131
6.2	Temporal changes in mean and standard error of mean of rectal temperature of goats following intravenous injection of 0.1 mg/kg xylazine under three different environmental conditions.....	132
7.1	Calibration curve in plasma of the mean xylazine concentration and peak areas.....	157
7.2	Representative chromatograms of blank goat plasma extract (A), goat plasma spiked with 100ng/ml xylazine (X) with extraction (B) and without extraction (C).....	158
7.3a	Plasma xylazine concentration versus time in goats under three different environmental conditions.....	161
7.3b	Semi-logarithmic plot of plasma xylazine concentration versus time in goats under three different environmental conditions.....	162
7.4	Two compartmental open model with first order rate constants.....	163

LIST OF TABLES

3.1	Changes in haemocytological variables (mean \pm SEM) in goats following intravenous injection of 0.1 mg/kg xylazine hydrochloride under three different environmental conditions, (n = 6).....	72
4.1	Means (\pm SEM) of arterial blood gas and acid-base balance parameter in goats following intravenous injection of 0.1 mg/kg xylazine hydrochloride under three different environmental conditions, (n = 6)	95
7.1	Accuracy and precision of xylazine in plasma.....	157
7.2	Mean percentage recovery of xylazine from spiked plasma samples.....	158
7.3	Mean pharmacokinetic parameters describing the plasma disposition of xylazine in goats after intravenous administration under three different environmental conditions.....	164
10.1	Individual pharmacokinetic results derived by non-compartmental analysis.	177
10.2	Individual pharmacokinetic results derived from compartmental analysis	178

ABSTRACT

The clinical use of xylazine may result in morbidity and mortality in small ruminants, and it was suspected that exposure to changes in environmental temperature may contribute to these effects.

Xylazine hydrochloride was administered intravenously at a dose of 0.1 mg/kg to a group of six indigenous domestic goats with a mean body mass of 28.2 kg. Xylazine was administered at a room temperature of 14° C and relative humidity of 33%, at 24° C and a relative humidity of 55%, and at 34° C with a relative humidity of 65%. The following variables were evaluated: clinical behaviour, cardiopulmonary function, haematology, acid-base balance, plasma glucose and insulin, body temperature, and the pharmacokinetic characteristics of xylazine.

Xylazine administration resulted in transient restlessness, followed by sedation, muscle relaxation, and salivation. The onset of these clinical signs was not influenced by environmental conditions.

Administration of xylazine resulted in a transient increase in respiratory rate in the 24 and 34° C environments. In the 14° C environment, the respiratory rate

decreased significantly ($p < 0.05$) from baseline and continued to decrease for the full duration of the 60 minutes observation period. Heart rate decreased in all three environments, but this decrease was only significant in the 14° C environment for the duration of the observation period.

Changes in haemoglobin concentration, haematocrit, red blood cell count and mean red blood cell volume were significantly ($p < 0.05$) different 15 minutes after xylazine administration and continued to be so for the duration of the observation period. Total serum protein changed significantly ($p < 0.05$) in the 24° and 34° C environments from 15 minutes after xylazine administration. The white cell count changed significantly ($p < 0.05$) from 15 minutes after xylazine administration for the duration of the observation period in all three environments.

Significant ($p < 0.05$) changes occurred after xylazine administration in acid-base balance and arterial blood gas variables independent of environmental conditions. Arterial pH and the partial pressure of oxygen decreased significantly within 5 minutes of xylazine administration, and the partial pressure of carbon dioxide, total carbon dioxide and base excess increased significantly ($p < 0.05$).

Environmental conditions had no observable influence on plasma glucose and

insulin concentration. Significant ($p < 0.05$) changes occurred in all three environments.

Environmental conditions had no influence on body temperature in the control (untreated) animals. Following the administration of xylazine, the body temperature of the goats in the 14 and 24° C environments was significantly ($p < 0.05$) lower than that of the goats in the 34° C environment. The maximum decrease in oesophageal temperature of 1.57° C was observed 60 minutes after xylazine administration to goats maintained in the 14° C environment.

Environmental conditions had no influence on all of the pharmacokinetic parameters of xylazine hydrochloride evaluated.

It is concluded that apart from changes in body temperature, changes that occurred in clinical and pharmacokinetic variables after xylazine administration, were independent of the three environmental temperature and humidity conditions.

OPSOMMING

Die kliniese gebruik van xilasien mag lei tot morbiditeit en mortaliteit by kleinvee, en die vermoede het bestaan dat blootstelling aan skommeling in omgewingstemperatuur hiertoe mag bydra. Die doel van hierdie studie was om die invloed van temperatuur en relatiewe humiditeit op 'n verskeidenheid van kliniese veranderlikes en die farmakokinetika van xilasien hidrochloried in bokke te bepaal.

Xilasien was intraveneus toegedien teen 'n dosis van 0.1 mg/kg aan 'n groep van ses inheemse, gedomestiseerde bokke met 'n gemiddelde liggaamsmassa van 28.2 kg.

Eerstens is xilasien toegedien by 'n temperatuur van 14° C en 'n relatiewe humiditeit van 33%, tweedens by 24°C en 'n relatiewe humiditeit van 55%, en laastens by 34° C met 'n relatiewe humiditeit van 65%. Die volgende veranderlikes is geëvalueer: kliniese gedrag, kardiopulmonale funksie, hematologie, suur-basis balans, arteriële bloedgasse, plasma glukose en insulien, liggaamstemperatuur en die farmakokinetiese eienskappe van xilasien.

Xilasientoediening het aanvanklik 'n kort periode van rusteloosheid veroorsaak gevolg deur kalmering, spierverslapping en speekselvloei. Die aanvang van hierdie kliniese tekens was nie deur verandering in eksperimentele omgewingstoestande beïnvloed nie.

Toediening van xilasien het die asemhalingstempo aanvanklik verhoog by die 24 en 34° C omgewingstoestande, waarna dit weer begin daal het. By 14° C het die asemhalingstempo betekenisvol ($p < 0.05$) gedaal vanaf die basislyn gedurende die 60 minute observasietydperk. Harttempo het ook tydens al drie omgewingstoestande gedaal. Die harttempo het slegs tydens die 14° C omgewingstoestand statisties betekenisvol ($p < 0.05$) vir die volle duur van die observasietydperk gedaal.

Veranderinge in hemoglobienkonsentrasie, hematokrit, eritrosietelling en gemiddelde eritrosietvolume het betekenisvol ($p < 0.05$) verander, 15 minute na toediening van xilasien vir die volle duur van die observasietydperk. Totale serum proteïene het tydens 24 en 34° C omgewingstoestande betekenisvol ($p < 0.05$) verander vanaf 15 minute na toediening. Die witseltelling het ook vanaf 15 minute na toediening vir die duur van die observasietydperk by al drie omgewingstoestande betekenisvol ($p < 0.05$) verander.

Betekenisvolle veranderings ($p < 0.05$) in die suur-basis balans en arteriële bloed gas veranderlikes het onafhanklik van omgewingstoestande na toediening van xilasien voorgekom. Arteriële pH en partiële suurstofdruk het betekenisvol ($p < 0.05$) binne 5 minute na toediening van xilasien gedaal, terwyl die partiële druk van

koolsuurgas, totale koolsuurgas en basisoorskot betekenisvol ($p < 0.05$) verhoog het. Eksperimentele omgewingstoestande het geen invloed op plasma glukose en insulien vlakke gehad nie. Statisties betekenisvolle veranderinge ($p < 0.05$) het wel by dié veranderlikes na xilasientoediening in al drie omgewingstoestande voorgekom.

Omgewingstoestande het geen invloed op liggaamstemperatuur in die kontrole groep (onbehandelde) bokke gehad nie. Die toediening van xilasien het tot 'n betekenisvolle daling in liggaamstemperatuur by 14 en 24° C omgewingstoestande gelei in vergelyking met die veranderinge wat by die 34° C omgewingstoestand waargeneem is. 'n Maksimale daling van 1.57° C in oesofageale-temperatuur het 60 minute na die toediening van xilasien aan bokke by die 14° C omgewingstoestand voorgekom.

Die eksperimentele omgewingstoestande het geen invloed op plasma halflewe en volume van verspreiding van xilasien gehad nie.

Ten slotte dit gevind dat, afgesien vir veranderinge in liggaamstemperatuur, het afwykinge in kliniese en farmakokinetiese veranderlikes na xilasientoediening onafhanklik van die eksperimentele omgewingstoestande plaasgevind.